Understanding Electrolyte Disorders: Causes, Symptoms, and Treatment

What Are Electrolytes?

Electrolyte disorders are among the most common findings in hospitalized patients; hyponatremia alone affects approximately 15–30% of admissions and is associated with a 2- to 3-fold increase in in-hospital mortality (NEJM 2015). Electrolytes are electrically charged minerals dissolved in body fluids -- primarily blood, urine, and the fluid inside and surrounding cells. When dissolved, they dissociate into positively charged cations and negatively charged anions, creating the ionic environment that makes all biological electricity possible. Every heartbeat, every nerve impulse, every muscle contraction, and every transport of nutrients across cell membranes depends on the precise balance of these charged particles.

The key electrolytes in clinical medicine are sodium (Na+), potassium (K+), calcium (Ca2+), magnesium (Mg2+), phosphate (PO4 3-), chloride (Cl-), and bicarbonate (HCO3-). Each has a distinct distribution within the body and a unique set of physiological roles.

Sodium (Na+) is the dominant extracellular cation. Normal serum sodium ranges from 135 to 145 mEq/L. It is the primary determinant of plasma osmolality and therefore controls fluid distribution between the intracellular and extracellular compartments. When sodium rises, water follows it out of cells; when sodium falls, water moves in. This is why sodium disorders manifest primarily as neurological symptoms -- brain cells are particularly sensitive to changes in volume.

Potassium (K+) is the dominant intracellular cation, with approximately 98 percent of total body potassium residing inside cells. Normal serum potassium ranges from 3.5 to 5.0 mEq/L, representing only a tiny fraction of total body stores. The steep concentration gradient between intracellular potassium (approximately 140 mEq/L) and extracellular potassium (3.5 to 5.0 mEq/L) is the main determinant of the resting membrane potential of excitable cells, making potassium the critical electrolyte for cardiac and skeletal muscle function.

Calcium (Ca2+) has a normal serum range of 8.5 to 10.5 mg/dL. Approximately 99 percent of body calcium resides in bones as hydroxyapatite, providing structural strength. The small fraction in blood exists in three forms: ionized (approximately 45 percent, the physiologically active form), protein-bound (approximately 40 percent, primarily to albumin), and complexed to anions (approximately 15 percent). Calcium is essential for muscle contraction, neurotransmitter release, blood clotting, and enzymatic reactions throughout the body.

Magnesium (Mg2+) is predominantly intracellular, with normal serum levels of 1.8 to 2.5 mg/dL representing only about 1 percent of total body stores. Magnesium is a cofactor for over 300 enzymatic reactions, including those involved in ATP synthesis, DNA replication, and protein synthesis. It is also required for the proper function of sodium-potassium ATPase pumps and for PTH secretion, making it a critical regulator of both potassium and calcium homeostasis.

Phosphate (PO4 3-) has a normal serum range of 2.5 to 4.5 mg/dL. Like magnesium, most phosphate is intracellular. It is a structural component of ATP, cell membranes (phospholipids), and nucleic acids (DNA and RNA). It is also incorporated into bone as hydroxyapatite. Adequate phosphate is essential for red blood cell oxygen delivery (through 2,3-DPG), muscle energy metabolism, and intracellular signaling.

Chloride (Cl-) is the dominant extracellular anion, with a normal serum range of 98 to 106 mEq/L. It moves in tandem with sodium to maintain electrical neutrality and is integral to acid-base balance, particularly in the kidney's handling of bicarbonate.

Bicarbonate (HCO3-) has a normal serum range of 22 to 29 mEq/L and is the primary buffer of blood pH. It is produced by the kidneys, and its regulation is central to acid-base homeostasis.

Electrolyte Homeostasis: Kidneys and Hormones

The body maintains electrolyte balance through an intricate system of hormonal signals and renal responses. The kidneys filter approximately 180 liters of blood per day, and the tubular segments of the nephron selectively reabsorb or secrete electrolytes in response to hormonal signals to maintain precise serum concentrations.

The renin-angiotensin-aldosterone system (RAAS) is the master regulator of sodium and potassium balance. When sodium levels fall or blood pressure drops, the kidney releases renin, which ultimately stimulates aldosterone secretion from the adrenal cortex. Aldosterone acts on the distal nephron to increase sodium reabsorption and potassium excretion. Antidiuretic hormone (ADH, also called vasopressin) regulates free water reabsorption in the collecting duct in response to changes in plasma osmolality or blood volume. Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23) regulate calcium and phosphate reabsorption. These regulatory systems are tightly coupled -- a disturbance in one electrolyte almost always impacts others, which is why thorough assessment and concurrent correction is essential in clinical practice.

---

What Causes Sodium Disorders?

Hyponatremia (Sodium below 135 mEq/L)

Hyponatremia is the most common electrolyte disorder in clinical medicine, affecting approximately 15 to 30 percent of hospitalized patients. Despite its frequency, it is frequently mismanaged, with both over-rapid and under-rapid correction carrying serious risks. Clinicians must approach hyponatremia systematically, classifying it by tonicity, then by volume status, to identify the underlying cause and guide treatment.

Classification by tonicity is the essential first step. Hypotonic hyponatremia (plasma osmolality below 275 mOsm/kg) represents true hyponatremia, where there is a genuine excess of water relative to sodium. Isotonic hyponatremia -- also called pseudohyponatremia -- occurs when extreme elevations in plasma lipids or proteins displace water from plasma, artificially lowering the measured sodium concentration without any true change in osmolality or clinical consequence. This is increasingly rare with modern direct ion-selective electrode assays. Hypertonic hyponatremia occurs when a osmotically active substance such as glucose draws water from cells into the extracellular space, diluting sodium. Severe hyperglycemia is the classic example, and the Sodium Correction Calculator automatically adjusts the measured sodium for glucose levels to reveal the true underlying sodium status -- for every 100 mg/dL rise in glucose above 100 mg/dL, the corrected sodium should be increased by approximately 1.6 to 2.4 mEq/L.

Classification by volume status in hypotonic hyponatremia guides treatment. This assessment relies on clinical examination (skin turgor, mucous membranes, jugular venous pressure, edema) and, when needed, urine sodium and urine osmolality.

• Hypovolemic hyponatremia (low total body sodium AND low total body water, with water loss proportionally less than sodium loss) occurs with salt wasting from the kidneys (diuretics, cerebral salt wasting, adrenal insufficiency) or from extrarenal sources (vomiting, diarrhea, burns, pancreatitis). The urine sodium is typically below 20 mEq/L in extrarenal causes (kidneys appropriately conserving sodium) but above 20 mEq/L in renal causes. Treatment is isotonic (normal) saline to replace the volume deficit.

• Euvolemic hyponatremia (normal total body sodium, expanded total body water) is most often caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). SIADH results from inappropriately elevated ADH secretion, causing free water retention without sodium retention. Causes include central nervous system diseases (meningitis, stroke, subarachnoid hemorrhage, head trauma), pulmonary diseases (pneumonia, tuberculosis, positive-pressure ventilation), malignancies (particularly small cell lung cancer, which secretes ectopic ADH), and numerous medications (SSRIs, carbamazepine, cyclophosphamide, MDMA, oxytocin). Hypothyroidism and glucocorticoid deficiency can also cause euvolemic hyponatremia by different mechanisms. In SIADH, the urine osmolality is inappropriately high (above 100 mOsm/kg) and urine sodium is typically above 40 mEq/L. Treatment is primarily fluid restriction (800 to 1,000 mL per day); vaptans (tolvaptan, conivaptan) block ADH receptors and can be used for resistant cases under careful monitoring.

• Hypervolemic hyponatremia (elevated total body sodium AND elevated total body water, with water retention exceeding sodium retention) occurs in heart failure, cirrhosis, and nephrotic syndrome. Despite having excess total body sodium, effective arterial blood volume is reduced, triggering compensatory ADH and RAAS activation that retains water in excess of sodium. Clinically, patients present with edema, ascites, or pulmonary congestion. The urine sodium is typically below 20 mEq/L (renal sodium avidity). Treatment focuses on the underlying condition -- diuretics and fluid restriction for heart failure and cirrhosis, with loop diuretics being preferred because thiazides can worsen hyponatremia.

Symptoms of hyponatremia depend critically on both the absolute sodium level and the rate of decline. The brain can partially adapt to chronic hyponatremia by extruding intracellular osmoles, reducing cerebral swelling. Acute hyponatremia (developing within 48 hours) carries greater risk at any given sodium level because adaptation has not had time to occur.

Mild hyponatremia (sodium 130 to 134 mEq/L) may cause nausea, malaise, and headache. Moderate hyponatremia (sodium 125 to 129 mEq/L) causes confusion, lethargy, and gait disturbances. Severe hyponatremia (sodium below 125 mEq/L, or rapid decline) can cause seizures, respiratory arrest, coma, and death from cerebral herniation.

Treatment and the critical correction rate limit: In chronic hyponatremia, the brain has extruded organic osmoles to adapt to the low-sodium environment. Correcting sodium too rapidly reverses this adaptation too quickly, causing water to leave brain cells faster than they can regain osmoles. This produces osmotic demyelination syndrome (ODS), also called central pontine myelinolysis -- a potentially devastating neurological injury causing dysarthria, dysphagia, seizures, locked-in syndrome, and even death. The correction rate should not exceed 8 to 10 mEq/L per 24 hours (some guidelines recommend no more than 10 to 12 mEq/L per 24 hours in cases of very severe hyponatremia). In acute symptomatic hyponatremia (seizures, coma), hypertonic saline (3% NaCl) is used to raise sodium by 1 to 2 mEq/L per hour until symptoms resolve, after which correction must be slowed. Frequent sodium monitoring (every 2 to 4 hours) is mandatory during active correction.

Hypernatremia (Sodium above 145 mEq/L)

Hypernatremia almost always indicates a deficit of free water relative to total body sodium. This can result from inadequate water intake, excessive water loss, or (rarely) excess sodium administration. Unlike hyponatremia, which can occur with a wide variety of sodium/water combinations, hypernatremia is essentially always a water problem -- either the patient cannot drink enough (impaired thirst mechanism, physical inability to access water, altered consciousness) or they are losing water faster than they can replace it.

Causes of hypernatremia include:

• Diabetes insipidus (DI): Central DI results from inadequate ADH secretion due to damage to the hypothalamus or posterior pituitary (trauma, neurosurgery, tumors, ischemia, Langerhans cell histiocytosis). Nephrogenic DI results from renal resistance to ADH, caused by chronic lithium use (most common medication cause), hypercalcemia, hypokalemia, or inherited mutations. In both forms, massive dilute urine output (polyuria of 3 to 20 liters per day) leads to free water loss and hypernatremia if intake cannot keep pace. Central DI responds to desmopressin (DDAVP), while nephrogenic DI requires treating the underlying cause, thiazide diuretics, and sodium restriction.

• Osmotic diuresis: In diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), the high glucose load in the tubular fluid obligates water excretion, producing large volumes of dilute urine and free water loss. Mannitol and high-protein tube feeds can similarly cause osmotic diuresis.

• Extrarenal water losses: Fever, tachypnea, extensive burns, and high ambient temperatures increase insensible water losses. Severe diarrhea, particularly secretory diarrhea (rotavirus, cholera), can produce hypotonic stool losses.

Symptoms are neurological and arise from cell shrinkage as water moves out of neurons in response to elevated extracellular osmolality. Mild hypernatremia causes lethargy, irritability, and weakness. Severe hypernatremia causes confusion, muscle twitching, focal neurological deficits, and in extreme cases, intracranial hemorrhage from rupture of bridging veins as brain volume contracts. These neurological symptoms are particularly severe in children and the elderly.

Treatment requires calculating the free water deficit and replacing it gradually. The formula for free water deficit is: total body water (TBW) multiplied by (serum sodium divided by 140, minus 1). For example, a 70 kg older woman (TBW approximately 0.45 times body weight, or 31.5 L) with a sodium of 158 mEq/L would have a free water deficit of approximately 31.5 times (158/140 - 1), which equals 31.5 times 0.129, or approximately 4.1 liters. Correction should occur over 24 to 48 hours, with a target rate of correction no faster than 10 to 12 mEq/L per 24 hours to avoid cerebral edema. Ongoing losses must also be accounted for. The Serum Osmolality Calculator helps assess tonicity and can identify an osmolar gap (measured osmolality minus calculated osmolality) that might suggest an unmeasured osmole such as ethanol or methanol.

---

What Causes Potassium Disorders?

Hypokalemia (Potassium below 3.5 mEq/L)

Hypokalemia is one of the most common electrolyte abnormalities in clinical practice, particularly among hospitalized patients on diuretics or with ongoing gastrointestinal losses. Because 98 percent of body potassium is intracellular, the serum potassium level is a relatively poor indicator of total body stores -- a serum potassium of 3.0 mEq/L may represent a total body deficit of 200 to 400 mEq, while a serum potassium of 2.0 mEq/L may indicate a deficit exceeding 700 mEq.

Causes of hypokalemia are usefully categorized by mechanism:

• Gastrointestinal losses: Diarrhea is a major cause of potassium loss because stool water contains 20 to 50 mEq/L of potassium. Vomiting primarily causes hypokalemia through an indirect mechanism -- the resulting metabolic alkalosis increases urinary potassium excretion, and volume depletion activates aldosterone, which further drives renal potassium wasting.

• Renal potassium wasting: Loop diuretics (furosemide, bumetanide) are the most common medication cause of hypokalemia, blocking the Na-K-2Cl cotransporter in the thick ascending limb and increasing potassium delivery to the aldosterone-sensitive distal nephron. Thiazide diuretics also cause potassium wasting through a similar distal mechanism. Primary aldosteronism (Conn's syndrome) causes persistent hypokalemia with hypertension. Bartter syndrome (loop-equivalent defect) and Gitelman syndrome (thiazide-equivalent defect) are rare inherited tubular disorders that cause severe renal potassium and magnesium wasting. Hypomagnesemia perpetuates renal potassium wasting because magnesium is required for normal function of the ROMK potassium channel in the distal nephron -- this is why hypokalemia is often refractory to potassium replacement until magnesium is corrected simultaneously.

• Transcellular shifts (redistribution): Insulin drives potassium into cells via the sodium-potassium ATPase pump, which is why insulin is used therapeutically to treat hyperkalemia. Beta-2 adrenergic agonists (albuterol, epinephrine) do the same through a cyclic AMP-mediated mechanism. Metabolic and respiratory alkalosis shift potassium into cells (for every 0.1 unit rise in pH, potassium falls by approximately 0.4 to 0.6 mEq/L). Refeeding syndrome causes profound hypokalemia as insulin release drives potassium intracellularly when nutrition is reinitiated in malnourished patients.

Clinical effects of hypokalemia span several organ systems. Muscle weakness and fatigue are common at potassium levels below 3.0 mEq/L. Constipation and ileus result from smooth muscle dysfunction. Polyuria and polydipsia occur because hypokalemia impairs urinary concentrating ability (acquired nephrogenic DI). The cardiac effects are most dangerous: hypokalemia prolongs action potential repolarization, producing characteristic U waves on the ECG (positive deflections after the T wave, most visible in leads V2 and V3), and increasing the risk of premature ventricular contractions (PVCs) and potentially fatal ventricular arrhythmias including torsades de pointes, particularly when potassium is below 3.0 mEq/L. Hypokalemia also potentiates digoxin toxicity by competing for the same binding site on the sodium-potassium ATPase.

Treatment: Oral potassium chloride (KCl) is the preferred route for mild to moderate hypokalemia (potassium 2.5 to 3.5 mEq/L), as it is safer, more convenient, and restores both potassium and chloride (addressing any coexisting metabolic alkalosis). Intravenous potassium is reserved for severe hypokalemia (below 2.5 mEq/L) or for patients who cannot tolerate oral intake. The rate of IV potassium replacement must not exceed 20 mEq/hour via a peripheral IV line (higher rates risk phlebitis and ventricular arrhythmia) and should not exceed 40 mEq/hour via a central line with continuous cardiac monitoring. Hypomagnesemia must always be checked and corrected simultaneously, as hypokalemia will not fully correct without adequate magnesium repletion.

Hyperkalemia (Potassium above 5.0 mEq/L)

Hyperkalemia is the most immediately life-threatening electrolyte disorder because of its propensity to cause ventricular arrhythmias. While mild hyperkalemia is common and often asymptomatic, severe hyperkalemia (potassium above 6.5 mEq/L) or any hyperkalemia with ECG changes demands urgent treatment. Before acting on a high potassium result, pseudohyperkalemia should be considered -- a falsely elevated result due to potassium release from cells during sample processing (hemolysis from a difficult blood draw, prolonged transport, extreme leukocytosis above 100,000 cells/mcL, or extreme thrombocytosis above 1,000,000 platelets/mcL). Repeating the specimen with attention to careful phlebotomy technique resolves this.

Causes of true hyperkalemia include:

• Decreased renal excretion: This is the most common underlying mechanism. Chronic kidney disease (CKD) and end-stage renal disease (ESRD) reduce the nephron mass available for potassium secretion. Medications that block the RAAS are a major contributor: ACE inhibitors and ARBs reduce aldosterone stimulation; aldosterone antagonists (spironolactone, eplerenone) directly block renal potassium secretion; trimethoprim (in high doses) and amiloride block distal sodium channels that drive potassium secretion. Type 4 renal tubular acidosis (hyporeninemic hypoaldosteronism), common in diabetic nephropathy, causes mild to moderate hyperkalemia alongside a non-anion-gap metabolic acidosis.

• Increased potassium load: Excessive oral or IV potassium supplementation is a preventable cause. Rhabdomyolysis (from crush injury, severe exercise, statin toxicity, cocaine use) releases massive amounts of intracellular potassium. Tumor lysis syndrome (spontaneous or after chemotherapy) releases potassium, phosphate, and uric acid from lysed malignant cells. Massive blood transfusion exposes patients to the potassium leached from stored red blood cells.

• Transcellular shifts: Metabolic acidosis (particularly inorganic acidosis) drives potassium out of cells through electroneutral H+/K+ exchange (for every 0.1 unit fall in pH, potassium rises by approximately 0.4 to 0.6 mEq/L, though this varies). Insulin deficiency in diabetic ketoacidosis is the primary reason for hyperkalemia in DKA despite total body potassium depletion. Hyperkalemic periodic paralysis and succinylcholine administration also cause redistribution.

ECG changes in hyperkalemia are the key to determining urgency of treatment. The classic progression with rising potassium is: peaked, narrow, symmetric T waves (often the first ECG change); shortened QT interval; PR interval prolongation and widened P wave; loss of P waves; widening of the QRS complex; eventual fusion into a sinusoidal "sine wave" pattern; ventricular fibrillation or asystole. Any ECG change in the setting of hyperkalemia is a medical emergency requiring immediate treatment.

Treatment is tiered by urgency and mechanism:

1. Membrane stabilization (immediate, onset within minutes): Intravenous calcium gluconate (10 mL of 10% solution over 2 to 3 minutes) or calcium chloride (more potent but more irritating to veins) directly antagonizes the cardiac membrane effects of hyperkalemia without changing the serum potassium. Its effect lasts 30 to 60 minutes, during which definitive treatments must be initiated. It is indicated whenever there are ECG changes or severe hyperkalemia.

2. Shifting potassium into cells (onset 15 to 30 minutes): Regular insulin (10 units IV) combined with dextrose (25 g or 50 mL of 50% dextrose to prevent hypoglycemia) activates the sodium-potassium ATPase, driving potassium intracellularly and lowering serum potassium by 0.5 to 1.0 mEq/L for 4 to 6 hours. Nebulized albuterol (10 to 20 mg) also drives potassium into cells via beta-2 receptor stimulation and can lower potassium by an additional 0.5 to 1.0 mEq/L; it is additive to insulin. Sodium bicarbonate (in the setting of coexisting metabolic acidosis) shifts potassium intracellularly.

3. Removing potassium from the body: Furosemide (loop diuretic) enhances renal potassium excretion if renal function is adequate. Cation exchange resins -- patiromer (Veltassa) and sodium zirconium cyclosilicate (Lokelma) -- are newer, more effective agents that bind potassium in the GI tract and are now preferred over sodium polystyrene sulfonate (Kayexalate), which has a slower onset and greater risk of intestinal necrosis. Hemodialysis is the most rapid and reliable method for removing potassium and is the definitive treatment for life-threatening hyperkalemia unresponsive to other measures, or in patients with severe renal failure.

---

What Causes Calcium Disorders?

Hypocalcemia (Corrected calcium below 8.5 mg/dL)

A critical pitfall in calcium interpretation is the influence of albumin. Because approximately 40 percent of serum calcium is bound to albumin, total measured calcium will be falsely low in hypoalbuminemic patients (common in hospitalized, malnourished, or critically ill patients) even when ionized (active) calcium is normal. The corrected calcium formula adds 0.8 mg/dL for every 1 g/dL that albumin falls below 4.0 g/dL. For example, a patient with a measured calcium of 7.5 mg/dL and an albumin of 2.0 g/dL has a corrected calcium of 7.5 plus (4.0 - 2.0) times 0.8, which equals 7.5 plus 1.6, or 9.1 mg/dL -- entirely normal. The Corrected Calcium Calculator performs this adjustment automatically. When doubt exists, ionized calcium (measured directly by most modern analyzers) provides the most reliable assessment of true calcium status.

pH also affects calcium binding to albumin. Alkalosis increases binding, reducing ionized calcium and potentially precipitating symptoms of hypocalcemia even with a normal total calcium (as occurs in hyperventilation). Acidosis has the opposite effect, reducing binding and raising ionized calcium.

Causes of true hypocalcemia include:

• Hypoparathyroidism: The most common surgical cause is inadvertent parathyroid gland removal or devascularization during thyroidectomy (particularly total thyroidectomy for thyroid cancer). Autoimmune hypoparathyroidism is the most common non-surgical cause in adults.

• Hypomagnesemia: Magnesium is required both for PTH secretion from the parathyroid glands and for end-organ (renal and bone) responsiveness to PTH. Severe hypomagnesemia causes functional hypoparathyroidism, and hypocalcemia will not respond to calcium replacement alone until magnesium is corrected.

• Vitamin D deficiency and malabsorption: Vitamin D is necessary for intestinal calcium absorption. Deficiency from inadequate sun exposure, poor dietary intake, or malabsorption (celiac disease, post-bariatric surgery, short bowel syndrome) reduces GI calcium uptake. Chronic kidney disease impairs the final hydroxylation step (1-alpha hydroxylation) in the kidney that converts vitamin D to its active form, calcitriol, contributing to hypocalcemia and secondary hyperparathyroidism.

• Hungry bone syndrome: After parathyroidectomy for long-standing hyperparathyroidism, or after total thyroidectomy with removal of hyperfunctioning parathyroids, bones that were previously resorbing calcium rapidly now avidly take up calcium and phosphate as normal bone remodeling resumes. This can cause precipitous and prolonged hypocalcemia requiring aggressive replacement.

• Acute pancreatitis: Calcium is sequestered in areas of fat necrosis around the inflamed pancreas. The degree of hypocalcemia correlates with pancreatitis severity.

Symptoms of hypocalcemia reflect neuromuscular irritability due to decreased action potential threshold. Perioral numbness and tingling are often the first symptoms, followed by tingling in the fingertips and toes. Muscle cramps, carpopedal spasm (painful flexion of the wrist and metacarpophalangeal joints), and tetany can occur in moderate to severe hypocalcemia. Classic physical examination findings include Chvostek's sign (tapping the facial nerve just anterior to the ear produces ipsilateral facial muscle twitching -- has low specificity, present in about 10 percent of normocalcemic individuals) and Trousseau's sign (inflation of a blood pressure cuff above systolic pressure for 3 minutes produces carpal spasm due to ischemia-induced neural hyperexcitability -- more specific than Chvostek's). Life-threatening manifestations include laryngospasm, bronchospasm, seizures, and prolongation of the QT interval with associated ventricular arrhythmias.

Treatment: Symptomatic or severe hypocalcemia (corrected calcium below 7.5 mg/dL or ionized calcium below 1.0 mmol/L) requires intravenous calcium. Calcium gluconate (1 to 2 g IV over 10 to 20 minutes) is preferred over calcium chloride for peripheral administration because it is less irritating to veins (though calcium chloride provides three times more elemental calcium per volume and may be preferred in cardiac arrest or when a central line is available). Chronic management of hypoparathyroidism requires oral calcium supplements (calcium carbonate or calcium citrate) and active vitamin D (calcitriol 0.25 to 1.0 mcg daily, since patients cannot convert vitamin D to its active form without PTH). Recombinant PTH (teriparatide) and parathyroid hormone 1-84 (natpara) are emerging therapies for chronic hypoparathyroidism.

Hypercalcemia (Corrected calcium above 10.5 mg/dL)

More than 90 percent of hypercalcemia cases are caused by just two conditions: primary hyperparathyroidism (the most common cause in outpatients) and malignancy (the most common cause in hospitalized patients). Distinguishing between these and other causes is guided by measurement of PTH and PTHrP alongside the calcium level.

Causes of hypercalcemia include:

• Primary hyperparathyroidism: Usually caused by a single benign parathyroid adenoma (80 to 85 percent of cases). PTH is elevated despite elevated calcium (normally, elevated calcium should suppress PTH). Most patients have mild, asymptomatic hypercalcemia discovered incidentally on routine labs. Surgical parathyroidectomy is curative when indicated.

• Malignancy-associated hypercalcemia has three main mechanisms: (1) humoral hypercalcemia of malignancy, in which solid tumors (squamous cell carcinoma of the lung, head and neck, renal cell carcinoma, bladder cancer) secrete PTH-related protein (PTHrP), which mimics PTH action on bone and kidney but is not detected on the standard PTH assay; (2) local osteolytic hypercalcemia from bone metastases (breast cancer, multiple myeloma) activating osteoclasts; and (3) excess 1,25-vitamin D production by lymphomatous tissue, driving increased GI calcium absorption. Malignancy-associated hypercalcemia is often severe and associated with a poor prognosis.

• Granulomatous diseases (sarcoidosis, tuberculosis, histoplasmosis, berylliosis): Activated macrophages within granulomas express 1-alpha hydroxylase, producing excess calcitriol independent of PTH regulation.

• Other causes: Familial hypocalciuric hypercalcemia (FHH) is a benign autosomal dominant condition from loss-of-function mutations in the calcium-sensing receptor, causing mild lifelong hypercalcemia with low urinary calcium excretion -- important to identify because these patients do not benefit from parathyroid surgery. Thiazide diuretics reduce urinary calcium excretion and can unmask subclinical hypercalcemia. Milk-alkali syndrome from excessive calcium carbonate ingestion. Vitamin D toxicity from excessive supplementation.

Symptoms of hypercalcemia are classically summarized as "bones, stones, groans, and psychic moans":

• Bones: Bone pain and fractures from osteitis fibrosa cystica in severe primary hyperparathyroidism
• Stones: Kidney stones (calcium oxalate or calcium phosphate) from hypercalciuria
• Groans: Nausea, vomiting, constipation, and abdominal pain from smooth muscle hypomotility; pancreatitis
• Psychic moans: Depression, anxiety, cognitive impairment, and confusion; fatigue and muscle weakness

The ECG in hypercalcemia classically shows a shortened QT interval, the inverse of hypocalcemia.

Severity classification guides urgency of treatment: mild hypercalcemia (below 12 mg/dL) is often asymptomatic and managed outpatient; moderate hypercalcemia (12 to 14 mg/dL) produces symptoms; severe hypercalcemia (above 14 mg/dL) constitutes a hypercalcemic crisis with risk of lethal arrhythmias, severe dehydration (calcium causes nephrogenic DI), acute kidney injury, and altered consciousness.

Treatment of acute severe hypercalcemia:

1. IV normal saline at 200 to 300 mL/hour restores volume (hypercalcemia causes obligate urinary water losses leading to dehydration) and increases renal calcium excretion. This is the immediate first step.
2. Loop diuretics (furosemide) after volume repletion to further enhance calciuresis -- but never before adequate rehydration, as they worsen dehydration.
3. Bisphosphonates: Zoledronic acid (4 mg IV over 15 minutes) or pamidronate (60 to 90 mg IV over 2 to 4 hours) inhibit osteoclast-mediated bone resorption. Onset is 24 to 48 hours but effect lasts weeks to months, making these the cornerstone of treatment for malignancy-associated hypercalcemia.
4. Calcitonin (4 international units/kg subcutaneously every 12 hours) has a rapid onset of 4 to 6 hours and can lower calcium by 1 to 2 mg/dL, but tachyphylaxis (loss of effect) develops within 24 to 48 hours, limiting its role to bridging therapy while bisphosphonates take effect.
5. Denosumab (a RANKL inhibitor) is an alternative to bisphosphonates for malignancy-associated hypercalcemia, particularly in patients with impaired renal function.
6. Dialysis for life-threatening hypercalcemia refractory to other measures or in patients with renal failure.

---

What Causes Magnesium Disorders?

Hypomagnesemia (Magnesium below 1.8 mg/dL)

Hypomagnesemia is among the most underrecognized electrolyte disorders in hospitalized patients, affecting approximately 10 to 20 percent of general hospital patients and up to 65 percent of ICU patients. It frequently goes undetected because it is not routinely included in standard laboratory panels, and because serum magnesium is a poor surrogate for total body magnesium stores (most magnesium is intracellular or in bone). A patient can have normal serum magnesium yet be substantially magnesium-depleted, and conversely, a low serum magnesium reliably indicates deficiency.

Causes of hypomagnesemia include:

• Gastrointestinal losses: Chronic diarrhea, malabsorption syndromes (Crohn's disease, celiac disease, short bowel syndrome), and prolonged proton pump inhibitor (PPI) use (PPIs reduce intestinal magnesium absorption through an incompletely understood mechanism and can cause severe hypomagnesemia with long-term use). Alcoholic diarrhea and dietary inadequacy in alcohol use disorder are major contributors.

• Renal losses: Loop and thiazide diuretics inhibit tubular magnesium reabsorption. Cisplatin (and other platinum-based chemotherapy agents) directly damages proximal tubular cells, causing profound magnesuria that can persist for months after treatment. Diabetic nephropathy impairs tubular magnesium reabsorption, contributing to the electrolyte abnormalities common in poorly controlled diabetes.

Clinical significance of hypomagnesemia extends far beyond its direct effects because magnesium is required for homeostasis of two other key electrolytes. Magnesium is necessary for proper function of the ROMK (renal outer medullary potassium) channel, the primary channel through which the distal nephron secretes potassium into the urine. When magnesium is deficient, this channel becomes overactive, causing inappropriate renal potassium wasting and refractory hypokalemia. Similarly, magnesium is required for PTH synthesis and secretion, and for PTH action on bone and kidney. Severe hypomagnesemia therefore causes functional hypoparathyroidism with resulting hypocalcemia. The clinical implication is straightforward but often overlooked: always measure magnesium when treating hypokalemia or hypocalcemia, and always correct hypomagnesemia first.

ECG manifestations of hypomagnesemia include prolonged PR interval, widened QRS, and prolonged QT interval. Hypomagnesemia is an important precipitant of torsades de pointes (a form of polymorphic ventricular tachycardia associated with QT prolongation), particularly when combined with other QT-prolonging medications.

Symptoms include muscle cramps, tremor, fasciculations, weakness, nystagmus, ataxia, and in severe cases, tetany and Chvostek's and Trousseau's signs (indistinguishable from those of hypocalcemia).

Treatment: Oral magnesium (magnesium oxide 400 to 800 mg daily, or magnesium glycinate for better GI tolerance) is appropriate for mild, asymptomatic hypomagnesemia but commonly causes diarrhea at higher doses. Intravenous magnesium sulfate (2 g IV over 15 to 60 minutes, followed by infusion as needed) is used for severe or symptomatic hypomagnesemia, and is also the first-line treatment for torsades de pointes (2 g IV push) and for seizure prevention in eclampsia (4 to 6 g loading dose, then 2 g/hour maintenance infusion). Because most magnesium is intracellular, repletion may require repeated dosing over days to replenish total body stores even after serum magnesium normalizes.

Hypermagnesemia (Magnesium above 2.5 mg/dL)

Hypermagnesemia is rare in patients with normal kidney function, because the kidneys can efficiently excrete excess magnesium. It occurs almost exclusively in patients with impaired renal function who receive magnesium-containing products -- antacids (magnesium hydroxide), laxatives (magnesium citrate, magnesium sulfate), or IV magnesium for therapeutic purposes (eclampsia, torsades de pointes).

Symptoms progress predictably with rising magnesium levels:

• 4 to 5 mg/dL: Nausea, flushing, headache
• 5 to 7 mg/dL: Loss of deep tendon reflexes (this is the earliest neurological sign and should be monitored during IV magnesium infusions by checking patellar reflexes)
• 7 to 10 mg/dL: Lethargy, somnolence, hypotension, bradycardia, ECG changes (prolonged PR and QRS)
• 10 to 13 mg/dL: Respiratory depression and respiratory arrest (magnesium blocks neuromuscular junction transmission)
• Above 15 mg/dL: Cardiac arrest

Treatment requires stopping all magnesium sources immediately. Intravenous calcium gluconate (1 to 2 g IV) directly antagonizes magnesium's membrane effects and is indicated for life-threatening hypermagnesemia. IV fluids combined with furosemide enhance renal magnesium excretion in patients with preserved renal function. Dialysis is required for severe hypermagnesemia in patients with renal failure, as it rapidly removes magnesium.

---

What Causes Phosphate Disorders?

Hypophosphatemia affects approximately 30% of hospitalized patients and up to 80% of ICU patients; refeeding syndrome—a potentially fatal form—occurs in approximately 15% of severely malnourished patients within the first 4 days of nutritional repletion.

Hypophosphatemia (Phosphate below 2.5 mg/dL)

Phosphate, like magnesium, is predominantly intracellular, so serum phosphate may not accurately reflect total body phosphate stores. Most mild hypophosphatemia is asymptomatic and discovered incidentally. Severe hypophosphatemia (below 1.0 mg/dL) is a medical emergency because phosphate is required for ATP synthesis -- without adequate phosphate, cells cannot generate energy, leading to dysfunction across multiple organ systems.

Causes of hypophosphatemia:

• Refeeding syndrome is the most clinically critical cause and represents a potentially fatal complication of nutritional rehabilitation in malnourished patients. When carbohydrates are reintroduced after a period of starvation or severe malnutrition (anorexia nervosa, cancer cachexia, post-surgery patients), insulin secretion surges and drives phosphate, potassium, and magnesium from the extracellular space into cells alongside glucose. The resulting rapid decline in serum phosphate (and often potassium and magnesium) can cause severe, life-threatening organ failure. Prevention requires slow, gradual reintroduction of nutrition (typically starting at 10 to 20 kcal/kg/day) with proactive electrolyte monitoring and prophylactic supplementation in high-risk patients.

• Transcellular shifts: Insulin administration (particularly during DKA treatment) and respiratory alkalosis (hyperventilation) are common causes of acute phosphate redistribution. Post-parathyroidectomy hungry bone syndrome causes rapid intracellular phosphate uptake alongside calcium.

• Decreased GI absorption: Aluminum- and magnesium-containing antacids bind phosphate in the intestinal lumen and prevent absorption. Vitamin D deficiency reduces active intestinal phosphate transport. Malabsorption syndromes reduce overall nutrient absorption.

• Increased renal losses: Primary and secondary hyperparathyroidism increase renal phosphate excretion (PTH is phosphaturic). Genetic disorders including X-linked hypophosphatemia (mutations in PHEX causing elevated FGF-23) and oncogenic osteomalacia cause severe hypophosphatemia through renal phosphate wasting.

Consequences of severe hypophosphatemia (below 1.0 mg/dL):

• Respiratory muscle weakness and failure (hypophosphatemia is an important and underrecognized cause of difficulty weaning from mechanical ventilation)
• Hemolytic anemia (ATP depletion makes red blood cells rigid and susceptible to fragmentation)
• Rhabdomyolysis from skeletal muscle ATP depletion
• Platelet dysfunction and impaired immune function
• Encephalopathy, irritability, paresthesias, and in severe cases, seizures and coma
• Impaired myocardial contractility

Treatment: Mild hypophosphatemia can be managed with oral phosphate supplements (sodium or potassium phosphate salts). Moderate to severe hypophosphatemia or symptomatic cases require IV phosphate replacement (sodium phosphate or potassium phosphate IV, with doses and rates guided by severity and the need for concomitant potassium replacement). Close monitoring is essential during IV phosphate administration to avoid hypocalcemia (calcium and phosphate form insoluble calcium phosphate complexes when both are elevated), hyperphosphatemia, or volume overload.

Hyperphosphatemia (Phosphate above 4.5 mg/dL)

The kidneys are the primary route of phosphate excretion, so hyperphosphatemia occurs most commonly in the setting of impaired renal function. It is a near-universal complication of advanced CKD (stages 4 and 5) and end-stage renal disease, where the declining nephron mass can no longer adequately clear the daily phosphate load absorbed from dietary intake.

Causes and clinical context:

In CKD, hyperphosphatemia drives a cascade of metabolic complications. Elevated phosphate binds calcium, lowering serum calcium and stimulating PTH secretion -- a process called secondary hyperparathyroidism. The parathyroid glands hypertrophy and eventually become autonomous (tertiary hyperparathyroidism). This persistent PTH elevation causes renal osteodystrophy (a spectrum of bone disorders in CKD), and the elevated calcium-phosphate product promotes vascular and soft tissue calcification, which is a major contributor to the dramatically elevated cardiovascular mortality in CKD and dialysis patients.

Acute severe hyperphosphatemia can occur in tumor lysis syndrome (rapid release of intracellular phosphate from lysed malignant cells) and rhabdomyolysis. In these settings, the sudden rise in phosphate can cause acute symptomatic hypocalcemia and contribute to acute kidney injury by calcium phosphate crystal deposition in the renal tubules.

Hypoparathyroidism causes hyperphosphatemia because PTH normally promotes renal phosphate excretion -- without PTH, phosphate is retained.

Treatment of hyperphosphatemia in CKD:

• Dietary phosphate restriction (typically below 800 to 1,000 mg phosphate per day) is the foundation of management. Foods high in phosphate include dairy products, processed foods with phosphate additives, cola beverages, nuts, and legumes. Phosphate additives in processed foods are absorbed at nearly 100 percent efficiency compared to organic phosphate from whole foods, making their avoidance particularly effective.

• Phosphate binders are taken with meals to bind dietary phosphate in the GI lumen and prevent absorption. Non-calcium-based binders are preferred in many patients because calcium-based binders add to the calcium-phosphate burden: sevelamer carbonate (Renvela) is widely used and also has lipid-lowering properties; lanthanum carbonate (Fosrenol) is an alternative; and ferric citrate binds phosphate while also providing iron for anemia management in CKD. Calcium carbonate and calcium acetate are effective and inexpensive but should be used cautiously in patients with hypercalcemia or vascular calcification.

• Active vitamin D analogs (calcitriol, paricalcitol, doxercalciferol) address the secondary hyperparathyroidism by suppressing PTH synthesis, though they can raise calcium and phosphate levels if used without adequate phosphate control.

• Calcimimetics (cinacalcet) increase parathyroid gland sensitivity to calcium, suppressing PTH secretion and reducing both calcium and phosphate levels. Cinacalcet is used for secondary hyperparathyroidism in dialysis patients who have elevated PTH and calcium.

---

How Is the Anion Gap Used to Diagnose Metabolic Acidosis?

An elevated anion gap (above 12 mEq/L) is present in approximately 20% of metabolic acidosis cases and indicates accumulation of unmeasured anions such as lactate, ketones, or toxins—narrowing a broad differential to a focused workup. The anion gap is a calculated electrolyte parameter that identifies the presence of unmeasured anions in the blood, most commonly from accumulation of an organic acid. The formula is: Anion Gap equals Na+ minus (Cl- plus HCO3-). The normal anion gap is 8 to 12 mEq/L. The Anion Gap Calculator performs this calculation and applies the albumin correction.

A critical refinement is the albumin-corrected anion gap. Because albumin carries a net negative charge at physiological pH, it contributes significantly to the normal anion gap. Hypoalbuminemia, common in hospitalized and critically ill patients, reduces the anion gap by approximately 2.5 mEq/L for every 1 g/dL fall in albumin below 4.0 g/dL. Failure to correct for albumin can mask a true elevated anion gap acidosis in hypoalbuminemic patients.

Elevated anion gap metabolic acidosis (HAGMA) indicates the presence of an unmeasured anion from an accumulated acid. The mnemonic MUDPILES covers the major causes:

• M -- Methanol (formic acid metabolite)
• U -- Uremia (accumulation of uremic organic acids in renal failure)
• D -- Diabetic ketoacidosis (beta-hydroxybutyrate, acetoacetate)
• P -- Propylene glycol (found in IV lorazepam formulations; metabolized to lactic acid)
• I -- Isoniazid and Iron overdose
• L -- Lactic acidosis (from tissue hypoperfusion, metformin overdose, thiamine deficiency, liver failure, seizures, linezolid)
• E -- Ethylene glycol (oxalic acid metabolite, causing acute renal failure with calcium oxalate crystal deposits)
• S -- Salicylates (also cause a concurrent respiratory alkalosis from direct brainstem stimulation)

Normal anion gap (hyperchloremic) metabolic acidosis occurs when bicarbonate is lost and chloride is retained. Common causes are gastrointestinal bicarbonate losses (diarrhea is the most common cause outside the hospital) and renal tubular acidosis (the kidney fails to excrete adequate acid or fails to reclaim filtered bicarbonate). The urine anion gap (urine Na+ plus K+ minus Cl-) helps distinguish GI causes (negative urine anion gap, indicating appropriate renal ammonium excretion) from renal causes (positive urine anion gap, indicating impaired renal ammonium excretion).

The delta-delta ratio (delta anion gap divided by delta bicarbonate, i.e., (measured AG minus 12) divided by (24 minus measured HCO3-)) helps identify mixed acid-base disorders. A ratio between 1 and 2 suggests a pure elevated anion gap metabolic acidosis. A ratio below 1 suggests a concurrent normal anion gap metabolic acidosis. A ratio above 2 suggests a concurrent metabolic alkalosis.

The ABG Interpreter integrates arterial blood gas values (pH, PaCO2) with the serum bicarbonate to determine the primary acid-base disorder, assess the adequacy of respiratory and metabolic compensation, and identify mixed disorders. Normal values are: pH 7.35 to 7.45; PaCO2 35 to 45 mmHg; HCO3- 22 to 29 mEq/L.

---

How Are Electrolyte Disorders Approached Clinically?

Rapid correction of chronic hyponatremia at rates above 10–12 mEq/L per 24 hours causes osmotic demyelination syndrome in approximately 1–3% of cases; careful rate monitoring is therefore a life-critical aspect of electrolyte management. Managing electrolyte disorders effectively requires adhering to several foundational principles that transcend any individual electrolyte.

Always confirm unexpected abnormalities. Laboratory errors, hemolysis of blood samples, prolonged sample processing, and transcription errors are common enough that a single unexpected electrolyte result should be repeated before initiating aggressive treatment, unless the clinical picture and ECG clearly support the diagnosis. This is especially important for hyperkalemia (pseudohyperkalemia is common) and for profound single-electrolyte abnormalities without a clear clinical explanation.

Look for concurrent electrolyte disorders. Electrolytes are interdependent. The most clinically important co-occurrences are hypokalemia with hypomagnesemia (nearly universal -- magnesium depletion causes renal potassium wasting), hypocalcemia with hypomagnesemia (magnesium deficiency impairs PTH secretion and action), and metabolic alkalosis with hypokalemia and hypochloremia (the "contraction alkalosis" triad common with diuretic use or vomiting). Always check and replace magnesium alongside potassium and calcium.

Treat the patient, not the number. The rate of development of an electrolyte abnormality and the clinical symptoms it produces are as important as the absolute value. Acute hyponatremia at 128 mEq/L can cause seizures and require urgent treatment; chronic hyponatremia at 120 mEq/L in an asymptomatic patient with SIADH requires gradual correction. Similarly, the threshold for treating hyperkalemia depends heavily on the ECG and clinical context.

Determine and treat the underlying cause. Replacing potassium in a patient with Conn's syndrome or refractory diarrhea without addressing the underlying cause will lead to recurrent hypokalemia. Giving calcium without diagnosing and treating hypoparathyroidism will require lifelong supplementation. Electrolyte repletion is supportive therapy -- finding and addressing the root cause prevents recurrence and identifies potentially serious underlying diseases.

Monitor for target organ effects:

• Cardiac monitoring (ECG) is essential for significant potassium or calcium disorders
• Neurological status assessment is critical for sodium disorders
• Neuromuscular examinations (reflexes, Chvostek's and Trousseau's signs) for calcium and magnesium disorders
• Respiratory muscle assessment for severe hypophosphatemia in ICU patients
• Renal function and urine output to assess for ongoing losses and guide fluid management

Electrolyte calculators in clinical practice: The Serum Osmolality Calculator provides calculated osmolality from sodium, BUN, and glucose, allowing comparison with measured osmolality to identify an osmolar gap (suggesting ethanol, methanol, ethylene glycol, or mannitol). The Corrected Calcium Calculator adjusts total calcium for albumin level, preventing both under- and over-treatment of calcium disorders in hypoalbuminemic patients. The Sodium Correction Calculator adjusts measured sodium for hyperglycemia, ensuring that sodium management in DKA and HHS accounts for the true underlying sodium status. The Anion Gap Calculator calculates both the raw and albumin-corrected anion gap, guiding metabolic acidosis evaluation.

---

When to Seek Urgent Medical Care

Life-threatening electrolyte emergencies—including potassium above 6.5 mEq/L, sodium below 120 mEq/L, or calcium above 14 mg/dL—require emergency intervention and account for approximately 5% of all ICU admissions. Electrolyte disorders span a wide spectrum from incidental laboratory findings to life-threatening emergencies. The following findings require immediate medical evaluation or emergency care:

Sodium disorders:

• Altered consciousness, seizures, or focal neurological deficits in the setting of hyponatremia -- this represents severe symptomatic hyponatremia requiring urgent hypertonic saline correction
• Any patient with sodium below 120 mEq/L, regardless of symptoms, in an acute or unknown time course
• Altered consciousness with suspected hypernatremia in a patient unable to take oral fluids

Potassium disorders:

• Any ECG changes (peaked T waves, QRS widening, loss of P waves, sine wave pattern) associated with hyperkalemia -- this is a cardiac emergency requiring immediate calcium gluconate
• Severe hyperkalemia (potassium above 6.5 mEq/L), even without ECG changes, requires urgent treatment
• Severe hypokalemia (potassium below 2.5 mEq/L) with symptoms, or any hypokalemia with cardiac arrhythmias
• Muscle weakness severe enough to impair breathing in hypokalemia or hypomagnesemia

Calcium disorders:

• Tetany, laryngospasm, or seizures from severe hypocalcemia -- requires emergent IV calcium
• Severe hypercalcemia (calcium above 14 mg/dL) with altered mental status, severe dehydration, or cardiac arrhythmias -- requires urgent IV fluids and bisphosphonate therapy
• QT prolongation on ECG with hypocalcemia (risk of torsades de pointes)

Magnesium disorders:

• Torsades de pointes ventricular tachycardia -- IV magnesium sulfate 2 g is the treatment of choice regardless of the serum magnesium level
• Loss of deep tendon reflexes during IV magnesium therapy -- indicates impending respiratory depression, infusion must be stopped immediately

Phosphate disorders:

• Respiratory muscle weakness or inability to wean from mechanical ventilation in the setting of severe hypophosphatemia (below 1.0 mg/dL) -- requires urgent IV phosphate replacement
• Altered consciousness or seizures from severe hypophosphatemia

Electrolyte disorders are among the most common and consequential conditions in medicine. Familiarity with their presentations, underlying mechanisms, and treatment principles -- supported by accurate use of clinical calculators for corrected values -- enables early recognition and safe, effective management that prevents serious outcomes.